{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:07:58Z","timestamp":1783040878274,"version":"3.54.6"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"High-level Talent Research Start-up Project of Affiliated Hospital of Guangdong Medical University","award":["GCC2023027"],"award-info":[{"award-number":["GCC2023027"]}]},{"name":"Industry-University-Research Innovation Fund for Chinese Universities - New Generation Information Technology Innovation Project","award":["2023IT023"],"award-info":[{"award-number":["2023IT023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13555-025-01514-y","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T07:41:36Z","timestamp":1755330096000},"page":"2983-2996","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Characteristics of Super Responders to Anti-IL-4R\u03b1 Biologic Therapy in Atopic Dermatitis"],"prefix":"10.1007","volume":"15","author":[{"given":"Litian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linglu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"issue":"12","key":"1514_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136\u201343.","journal-title":"N Engl J Med"},{"issue":"2","key":"1514_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","volume":"123","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144\u201351.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"1514_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/DER.0000000000000340","volume":"29","author":"T Gavrilova","year":"2018","unstructured":"Gavrilova T. Immune dysregulation in the pathogenesis of atopic dermatitis. Dermatitis. 2018;29(2):57\u201362.","journal-title":"Dermatitis"},{"key":"1514_CR4","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/DDDT.S457761","volume":"18","author":"M Wang","year":"2024","unstructured":"Wang M, Gao XH, Zhang L. A review of dupilumab in the treatment of atopic dermatitis in infants and children. Drug Des Devel Ther. 2024;18:941\u201351.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"1514_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13899","volume":"17","author":"MR McCann","year":"2024","unstructured":"McCann MR, Kosloski MP, Xu C, et\u00a0al. Dupilumab: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(8): e13899.","journal-title":"Clin Transl Sci"},{"key":"1514_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082867","author":"G Yang","year":"2020","unstructured":"Yang G, Seok JK, Kang HC, et\u00a0al. Skin barrier abnormalities and immune dysfunction in atopic dermatitis. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21082867.","journal-title":"Int J Mol Sci"},{"issue":"3 Suppl 1","key":"1514_CR7","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","volume":"78","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Hong HC, Eshtiaghi P, et\u00a0al. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3 Suppl 1):S28-s36.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1514_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","volume":"23","author":"LA Beck","year":"2022","unstructured":"Beck LA, Deleuran M, Bissonnette R, et\u00a0al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23(3):393\u2013408.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"1514_CR9","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1016\/j.jaip.2024.08.054","volume":"12","author":"P Chokevittaya","year":"2024","unstructured":"Chokevittaya P, Jirattikanwong N, Thongngarm T, et\u00a0al. Factors associated with dupilumab response in atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2024;12(11):3044\u201356.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"1514_CR10","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jaad.2020.08.127","volume":"84","author":"LFM Ari\u00ebns","year":"2021","unstructured":"Ari\u00ebns LFM, van der Schaft J, Spekhorst LS, et\u00a0al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-week results from the Dutch BioDay registry. J Am Acad Dermatol. 2021;84(4):1000\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1514_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.18176\/jiaci.0641","volume":"32","author":"E Nettis","year":"2022","unstructured":"Nettis E, Ferrucci SM, Ortoncelli M, et\u00a0al. Use of dupilumab in 543 adult patients with moderate-to-severe atopic dermatitis: a multicenter, retrospective study. J Investig Allergol Clin Immunol. 2022;32(2):124\u201332.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"3","key":"1514_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1365-2133.1994.tb08530.x","volume":"131","author":"HC Williams","year":"1994","unstructured":"Williams HC, Burney PG, Hay RJ, et\u00a0al. The U.K. Working Party\u2019s diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131(3):383\u201396.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1514_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.4103\/0366-6999.178960","volume":"129","author":"P Liu","year":"2016","unstructured":"Liu P, Zhao Y, Mu ZL, et\u00a0al. Clinical features of adult\/adolescent atopic dermatitis and Chinese criteria for atopic dermatitis. Chin Med J (Engl). 2016;129(7):757\u201362.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"1514_CR14","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/jdv.15979","volume":"34","author":"R Cheng","year":"2020","unstructured":"Cheng R, Zhang H, Zong W, et\u00a0al. Development and validation of new diagnostic criteria for atopic dermatitis in children of China. J Eur Acad Dermatol Venereol. 2020;34(3):542\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10247","key":"1514_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360.","journal-title":"Lancet"},{"issue":"2","key":"1514_CR16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2018.09.035","volume":"80","author":"YW Yew","year":"2019","unstructured":"Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390\u2013401.","journal-title":"J Am Acad Dermatol"},{"key":"1514_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115729","author":"GS Bocheva","year":"2021","unstructured":"Bocheva GS, Slominski RM, Slominski AT. Immunological aspects of skin aging in atopic dermatitis. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22115729.","journal-title":"Int J Mol Sci"},{"key":"1514_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.835675","volume":"10","author":"B Chen","year":"2022","unstructured":"Chen B, Yang J, Song Y, et\u00a0al. Skin immunosenescence and type 2 inflammation: a mini-review with an inflammaging perspective. Front Cell Dev Biol. 2022;10: 835675.","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"1514_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","volume":"22","author":"P Kolkhir","year":"2023","unstructured":"Kolkhir P, Akdis CA, Akdis M, et\u00a0al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat Rev Drug Discov. 2023;22(9):743\u201367.","journal-title":"Nat Rev Drug Discov"},{"key":"1514_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101422","volume":"71","author":"A Santoro","year":"2021","unstructured":"Santoro A, Bientinesi E, Monti D. Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? Ageing Res Rev. 2021;71: 101422.","journal-title":"Ageing Res Rev"},{"issue":"10348","key":"1514_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, et\u00a0al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273\u201382.","journal-title":"Lancet"},{"issue":"4","key":"1514_CR22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjd.20690","volume":"186","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Wu L, Lu Q, et\u00a0al. The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2022;186(4):633\u201341.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1514_CR23","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jamadermatol.2024.2192","volume":"160","author":"AM Drucker","year":"2024","unstructured":"Drucker AM, Lam M, Prieto-Merino D, et\u00a0al. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. JAMA Dermatol. 2024;160(9):936\u201344.","journal-title":"JAMA Dermatol"},{"key":"1514_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12165370","author":"C Gu","year":"2023","unstructured":"Gu C, Yao X, Li W. Burden of disease; the current status of the diagnosis and management of atopic dermatitis in China. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12165370.","journal-title":"J Clin Med"},{"issue":"1","key":"1514_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.anai.2020.08.002","volume":"126","author":"V Wang","year":"2021","unstructured":"Wang V, Boguniewicz J, Boguniewicz M, et\u00a0al. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):3\u201312.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"1514_CR26","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jaci.2022.10.023","volume":"151","author":"CFT Schuler","year":"2023","unstructured":"Schuler CFT, Billi AC, Maverakis E, et\u00a0al. Novel insights into atopic dermatitis. J Allergy Clin Immunol. 2023;151(5):1145\u201354.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1514_CR27","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","volume":"20","author":"P Facheris","year":"2023","unstructured":"Facheris P, Jeffery J, Del Duca E, et\u00a0al. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol. 2023;20(5):448\u201374.","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"1514_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1089\/derm.2023.0357","volume":"36","author":"F Russo","year":"2025","unstructured":"Russo F, Cioppa V, Lazzeri L, et\u00a0al. Evaluating the clinical meaning of Dermatology Life Quality Index scores between different phenotypes of atopic dermatitis in patients before and after biologic therapy with dupilumab. Dermatitis\u00ae. 2025;36(2):161\u20136.","journal-title":"Dermatitis\u00ae"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01514-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01514-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01514-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:06:55Z","timestamp":1758719215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01514-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1514"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01514-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Litian Zhang, Linglu Fang, Kun Zhong, and Ying Zhou have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the Ethics Review Committee of the Affiliated Hospital of Guangdong Medical University (KT2024-020-01). Written patient consent for publication was obtained by the National Clinical Research Center for Skin and Immune Diseases in China. The study was performed in accordance with the Declaration of Helsinki of 1964 and its later amendments. Data collection and handling complied with applicable laws, regulations, and guidance regarding patient protection, including patient privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}